Results: A significant anti-angiogenic effect of ketamine was observed in chick CAM in the in vivo setting, compared to the control group (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objectives: This study aims to investigate the effect of ketamine on angiogenesis.
📊
Key Findings & Data:Materials and methods: Between June 2021 and August 2021, chorioallantoic membrane (CAM) assay cell viability assay protocols and cell viability assay protocols were performed to investigate angiogenesis.
💡
Conclusion & Impact:Results: A significant anti-angiogenic effect of ketamine was observed in chick CAM in the in vivo setting, compared to the control group (p
🔬Design:Modeling & Simulation
📍Scope:2021 Verileri
⚙️Variables:Domain Parameters
Abstract
Objectives: This study aims to investigate the effect of ketamine on angiogenesis. Materials and methods: Between June 2021 and August 2021, chorioallantoic membrane (CAM) assay cell viability assay protocols and cell viability assay protocols were performed to investigate angiogenesis. While in vivo angiogenic property of ketamine was studied in the chick CAM model, its effect on in vitro cell proliferation was evaluated in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Results: A significant anti-angiogenic effect of ketamine was observed in chick CAM in the in vivo setting, compared to the control group (p
🔖
Cite This Article
İNCE, M. E., YILDIRIM, A. K., ÖZGÜRTAŞ, E. (2022). Anti-angiogenic response of ketamine in the in vitro and in vivo settings. Turkish journal of vascular surgery, Cilt: 31 - Sayı: 2, 67–71. https://ajindex.com/articles/614480
Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-66
Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
Tahergorabi Z, Khazaei M. A review on angiogenesis and its assays. Iran J Basic Med Sci 2012;15:1110-26
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42
Persson J. Ketamine in pain management. CNS Neurosci Ther 2013;19:396-402
Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for pain in adults and children with cancer: A systematic review and synthesis of the literature. Pain Med 2013;14:1505-17
Akata T. General anesthetics and vascular smooth muscle: Direct actions of general anesthetics on cellular mechanisms regulating vascular tone. Anesthesiology 2007;106:365-91
Bai X, Yan Y, Canfield S, Muravyeva MY, Kikuchi C, Zaja I, et al. Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species-mediated mitochondrial pathway. Anesth Analg 2013;116:869-80
Malsy M, Gebhardt K, Gruber M, Wiese C, Graf B, Bundscherer A. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol 2015;15:111
Yamaguchi F, Hirata Y, Akram H, Kamitori K, Dong Y, Sui L, et al. FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer 2013;13:468
Zhou X, Zhang P, Luo W, Zhang L, Hu R, Sun Y, et al. Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69. Cancer Med 2018;7:788-95
Fan N, Zhang M, Xu K, Ke X, Ding Y, Wang D, et al. Serum level of vascular endothelial growth factor decreased in chronic ketamine abusers. Drug Alcohol Depend 2015;152:57-61
Chang Y, Li JY, Jayakumar T, Hung SH, Lee WC, Manubolu M, et al. Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition. Int J Mol Sci 2017;18:2545